Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (81-90 of 153) with videos related to

Pageof 16
Sort By:
JACC. Cardiooncology|April 2, 2021
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint InhibitorsSarah Waliany, Joel W Neal, Sunil Reddy, et al.
Clinical Genitourinary Cancer|January 10, 2017
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line StudiesSamer Salah, Jae-Lyun Lee, Antonio Rozzi, et al.
JAMA Oncology|May 23, 2024
Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical TrialGladys M Rodriguez, Divya A Parikh, Kris Kapphahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 18, 2024
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancerHong Song, Maria Isabel Leonio, Valentina Ferri, et al.
Clinical Genitourinary Cancer|May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumLauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2022
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2021
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET ImagingHossein Jadvar, Jeremie Calais, Stefano Fanti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and CrizotinibAbhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Future Oncology (London, England)|November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumabChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Pageof 16

Showing results (81-90 of 153) with videos related to

Sort By:
Pageof 16
JACC. Cardiooncology|April 2, 2021
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint InhibitorsSarah Waliany, Joel W Neal, Sunil Reddy, et al.
Clinical Genitourinary Cancer|January 10, 2017
Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line StudiesSamer Salah, Jae-Lyun Lee, Antonio Rozzi, et al.
JAMA Oncology|May 23, 2024
Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical TrialGladys M Rodriguez, Divya A Parikh, Kris Kapphahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 18, 2024
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancerHong Song, Maria Isabel Leonio, Valentina Ferri, et al.
Clinical Genitourinary Cancer|May 3, 2014
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumLauren C Harshman, Nils Kroeger, Sun Young Rha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisoneCharles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2022
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial CancerChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2021
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET ImagingHossein Jadvar, Jeremie Calais, Stefano Fanti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2020
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and CrizotinibAbhishek Tripathi, Jeffrey G Supko, Kathryn P Gray, et al.
Future Oncology (London, England)|November 23, 2023
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumabChristopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, et al.
Pageof 16